AstraZeneca Pharmaceuticals LP

AstraZeneca Pharmaceuticals LP is a company in Wilmington, United States that has taken part in 3 EU-funded projects since 2023.

EU funding receivedNot recorded
EU projects3
As coordinator0
Running now3
First EU project2023
Latest project2025
CountryUnited States
EU registration (PIC)879183169
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are AstraZeneca Pharmaceuticals LP's own share of each project, not the project's full budget.

  • Horizon Europe€0 · 3 projects

Projects

3 EU-funded projects, newest first. Each links to the official record.

  • UNIFIEDAssociated partner

    Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies

    Horizon Europe · 2025–2030 · Project on CORDIS ↗

  • PharmEcoAssociated partner

    Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing

    Horizon Europe · 2024–2030 · Project on CORDIS ↗

  • GUIDE.MRDAssociated partner

    GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

    Horizon Europe · 2023–2028 · Project on CORDIS ↗

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • RNA
  • manufacturing engineering
  • proteins
  • vaccines

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime